StreetInsider.com News Articles

Freedom Broker Downgrades Sionna Therapeutics (SION) to Hold

Tue, 11 Aug 2026 10:09:06 -0400

Freedom Broker analyst Ilya Zubkov downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Hold with a price target of $5.00.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $4.50 yesterday.

Jones Trading Downgrades Sionna Therapeutics (SION) to Hold

Mon, 10 Aug 2026 15:53:12 -0400

Jones Trading analyst Debanjana Chatterjee downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Hold.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

LifeSci Capital Downgrades Sionna Therapeutics (SION) to Market Perform

Mon, 10 Aug 2026 15:21:56 -0400

LifeSci Capital analyst Gaurav Maini downgraded Sionna Therapeutics (NASDAQ: SION) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

BTIG Downgrades Sionna Therapeutics (SION) to Neutral, 'we were wrong on our PreciSION CF call'

Mon, 10 Aug 2026 15:14:56 -0400

BTIG analyst Kambiz Yazdi downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Neutral.

The analyst comments "We will be straightforward: we were wrong on our PreciSION CF call. PreciSION CF did not meet its key activity endpoint, reporting a mean placebo-adjusted sweat chloride change of -1.0 mmol/L (p=0.7), well short of the ≥10 mmol/L threshold we anticipated and that the trial was powered to detect. We are downgrading SION to Neutral."

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

BTIG Downgrades Sionna Therapeutics (SION) to Neutral, 'we were wrong on our PreciSION CF call'

Mon, 10 Aug 2026 15:14:56 -0400

BTIG analyst Kambiz Yazdi downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Neutral.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

Guggenheim Downgrades Sionna Therapeutics (SION) to Neutral

Mon, 10 Aug 2026 13:16:27 -0400

(Updated - August 10, 2026 1:16 PM EDT)

Guggenheim analyst Yatin Suneja downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Neutral.

The analyst commented: "Sionna's preciSION study of its NBD1 stabilizer combined with Vertex's Trikafta failed to show clinical benefit, and the program will be discontinued as management reassesses combo strategy. SION-451 (BID) + SION-2222 (TMD1 corrector, QD) is now the preferred pairing based on target coverage. Further profile updates are expected once management digests preciSION results. While NBD1 remains a differentiated biological target, we are moving to the sidelines pending more clarity. Current cash/basic share is ~$5.95. Downgrade to NEUTRAL and

Guggenheim Downgrades Sionna Therapeutics (SION) to Neutral

Mon, 10 Aug 2026 13:16:27 -0400

(Updated - August 10, 2026 1:16 PM EDT)

Guggenheim analyst Yatin Suneja downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Neutral.

RBC Capital Upgrades Sionna Therapeutics (SION) to Sector Perform

Mon, 10 Aug 2026 11:46:29 -0400

RBC Capital analyst Brian Abrahams upgraded Sionna Therapeutics (NASDAQ: SION) from Underperform to Sector Perform with a price target of $5.00.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

Citizens Downgrades Sionna Therapeutics (SION) to Market Perform

Mon, 10 Aug 2026 11:45:48 -0400

Citizens analyst Jonathan Wolleben downgraded Sionna Therapeutics (NASDAQ: SION) from Market Outperform to Market Perform.

For an analyst ratings summary and ratings history on Sionna Therapeutics click here. For more ratings news on Sionna Therapeutics click here.

Shares of Sionna Therapeutics closed at $51.04 yesterday.

Raymond James Downgrades Sionna Therapeutics (SION) to Market Perform

Mon, 10 Aug 2026 11:44:55 -0400

Raymond James analyst Chris Raymond downgraded Sionna Therapeutics (NASDAQ: SION) from Outperform to Market Perform.

The analyst comments "Downgrading SION shares to Market Perform after what we can only call a shocking outcome for PreciSION CF, the company’s P2a trial looking at ‘719 in combination with Trikafta. Recall the bar for success was an average of ≥10 mmol/L reduction of sweat chloride (SwCl) versus Trikafta alone, and even some bears were arguing that the bar should have been even higher. At just -1.0 mmol/L reduction, this is a clear failure. What’s worse, it appears DDI issues between ‘719 and Trikafta (which

Raymond James Downgrades Sionna Therapeutics (SION) to Market Perform

Mon, 10 Aug 2026 11:44:55 -0400

Raymond James analyst Chris Raymond downgraded Sionna Therapeutics (NASDAQ: SION) from Outperform to Market Perform.

Wedbush Downgrades Sionna Therapeutics (SION) to Neutral

Mon, 10 Aug 2026 10:42:14 -0400

Wedbush analyst Laura Chico downgraded Sionna Therapeutics (NASDAQ: SION) from Outperform to Neutral with a price target of $5.00 (from $53.00).

The analyst comments "Lowering rating to Neutral on SION, new $5 target. SION's Phase 2a PreciSION study failed to meet its endpoint, and the company will discontinue further SION-719 development. For SION-451, SION identified SION-2222 (QD) as the preferred combo agent, although advancement will take time as SION works through PreciSION data to determine strategy/trial design impacts. Bottom line, we hoped to see clear validation of SION's CF HBE platform via successful PreciSION data and while confounders impacted the study,

Wedbush Downgrades Sionna Therapeutics (SION) to Neutral

Mon, 10 Aug 2026 10:42:14 -0400

Wedbush analyst Laura Chico downgraded Sionna Therapeutics (NASDAQ: SION) from Outperform to Neutral with a price target of $5.00 (from $53.00).

Vertex stock jumps as rival cystic fibrosis drug fails trial

Mon, 10 Aug 2026 10:01:53 -0400

Investing.com -- Vertex Pharmaceuticals (NASDAQ: VRTX) shares rose 6% in early trading after Sionna Therapeutics reported its experimental cystic fibrosis treatment failed a key clinical trial, removing a potential competitive threat to Vertex's franchise.

Sionna Therapeutics (NASDAQ: SION) announced that its Phase 2a proof-of-concept trial of SION-719, tested as an add-on to Vertex's cystic fibrosis standard of care treatment Trikafta, failed to meet its primary endpoint of sweat chloride reduction. The study showed a non-statistically significant -1.0 mmol/L mean placebo-adjusted sweat chloride improvement.

Sionna said potential factors including sweat chloride variability and Trikafta exposure variability between treatment and placebo arms could have

Vertex stock jumps as rival cystic fibrosis drug fails trial

Mon, 10 Aug 2026 10:01:53 -0400

Sionna said potential factors including sweat chloride variability and Trikafta exposure variability between treatment and placebo arms could have

Vertex stock jumps as rival cystic fibrosis drug fails trial

Mon, 10 Aug 2026 10:01:53 -0400

Sionna said potential factors including sweat chloride variability and Trikafta exposure variability between treatment and placebo arms could have

Vertex stock jumps as rival cystic fibrosis drug fails trial

Mon, 10 Aug 2026 10:01:53 -0400

Sionna said potential factors including sweat chloride variability and Trikafta exposure variability between treatment and placebo arms could have

Stifel Downgrades Sionna Therapeutics (SION) to Hold

Mon, 10 Aug 2026 09:22:57 -0400

(Updated - August 10, 2026 9:22 AM EDT)

Stifel analyst Paul Matteis downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Hold with a price target of $7.00 (from $55.00).

The analyst comments "We are downgrading SION to Hold. Bottom line: we are disappointed, and very surprised, by the unequivocal failure of the ph2a readout. Going into these data, our view was that the 10mmol goal looked conservative based on SION's CFHBE data, and our analysis of SION-719 PK/PD. Instead, the minimal effect here (-1mmol) is hard to explain, leaves us puzzled, and even with the stock trading around cash, there's no clear

Stifel Downgrades Sionna Therapeutics (SION) to Hold

Mon, 10 Aug 2026 09:22:57 -0400

(Updated - August 10, 2026 9:22 AM EDT)

Stifel analyst Paul Matteis downgraded Sionna Therapeutics (NASDAQ: SION) from Buy to Hold with a price target of $7.00 (from $55.00).

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

Mon, 10 Aug 2026 08:04:51 -0400

Investing.com - U.S. stock index futures edged higher on Monday, while Dow futures were little changed, as investors scaled back hopes for a breakthrough in the Middle East and looked ahead to key inflation data due later this week for fresh clues on the Federal Reserve’s interest rate path.

By 06:27 ET (10:27 GMT), S&P 500 futures had risen by 11 points, or 0.1%, while Nasdaq 100 futures had gained 109 points, or 0.4%. Dow futures were mostly unchanged.

The cautious moves came as markets weighed fading expectations for progress toward a deal that could ease tensions in the Middle East. Investors were

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

Mon, 10 Aug 2026 08:04:51 -0400

By 06:27 ET (10:27 GMT), S&P 500 futures had risen by 11 points, or 0.1%, while Nasdaq 100 futures had gained 109 points, or 0.4%. Dow futures were mostly unchanged.

The cautious moves came as markets weighed fading expectations for progress toward a deal that could ease tensions in the Middle East. Investors were

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

Mon, 10 Aug 2026 08:04:51 -0400

By 06:27 ET (10:27 GMT), S&P 500 futures had risen by 11 points, or 0.1%, while Nasdaq 100 futures had gained 109 points, or 0.4%. Dow futures were mostly unchanged.

The cautious moves came as markets weighed fading expectations for progress toward a deal that could ease tensions in the Middle East. Investors were

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

Mon, 10 Aug 2026 08:04:51 -0400

By 06:27 ET (10:27 GMT), S&P 500 futures had risen by 11 points, or 0.1%, while Nasdaq 100 futures had gained 109 points, or 0.4%. Dow futures were mostly unchanged.

The cautious moves came as markets weighed fading expectations for progress toward a deal that could ease tensions in the Middle East. Investors were

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

Mon, 10 Aug 2026 08:04:51 -0400

By 06:27 ET (10:27 GMT), S&P 500 futures had risen by 11 points, or 0.1%, while Nasdaq 100 futures had gained 109 points, or 0.4%. Dow futures were mostly unchanged.

The cautious moves came as markets weighed fading expectations for progress toward a deal that could ease tensions in the Middle East. Investors were

Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout

Mon, 10 Aug 2026 08:04:51 -0400

By 06:27 ET (10:27 GMT), S&P 500 futures had risen by 11 points, or 0.1%, while Nasdaq 100 futures had gained 109 points, or 0.4%. Dow futures were mostly unchanged.

The cautious moves came as markets weighed fading expectations for progress toward a deal that could ease tensions in the Middle East. Investors were